- Preliminary Phase 1 trial results show three of four intubated COVID-19 patients were discharged after treatment via AGEN's new iNKT cell-therapy. Incredibly, two were extubated within 24 hours of dosing.
- As frantic families around the world demand access to AGEN's iNKT cell therapy for loved-ones, AGEN's Phase 2 trial could be enrolled faster than anticipated allowing a fast roadmap to EUA.
- Should AGEN's therapy cure severe COVID-19 patients, orders could be in the billions as the government stockpile AGEN's new therapy (that would likely also work on similar diseases like pneumonia).
- AGEN's other late-stage pipeline includes PD-1 & CTLA-4 compounds (NDA filings imminent), a next-generation CTLA-4 candidate also curing cancer, and QS-21 (the Shingrix adjuvant). All could be blockbusters by themselves.
- Finally, AGEN's latest highly anticipated asset in development, called VISION, has predicted which cancer therapy is best suited for patients with 85%+ accuracy.
For further details see:
Strong Buy: Agenus' iNKT Cell-Therapy Extubated 3 Of First 4 Severe COVID-19 Patients In P1 Trial